Hicks P E
Clin Exp Hypertens (1978). 1979;1(6):713-31. doi: 10.3109/10641967909068635.
The onset of DOCA-salt hypertension in male Sprague-Dawley rats was prevented during 11 weeks of oral treatment with indapamide (0.5, or 10.0 mg/kg) or propranolol (60 mg/kg) administered in the diet. The body weights of the indapamide treated groups were significantly (P < 0.01) greater, at weeks 4, 5, 6, 7 and 11, while the body weights and food intake of the propranolol treated group were significantly (P < 0.05) lower at week 11, than the control group. A significant reduction in heart wet weight (P < 0.001) was measured in the indapamide treated animals only. No significant diuresis nor natriuresis was measured in any group during week 11 of treatment. When all groups were subjected to an increased salt load, four weeks after cessation of drug treatment only the indapamide (10 mg/kg) treated animals failed to show an increased blood pressure. Vascular reactivity studies carried out six weeks after termination of drug treatment, indicated a significant (P < 0.01) reduction in pressor activity elicited by electrical stimulation of the entire sympathetic outflow in indapamide (10 mg/kg) treated pithed rats. No significant difference in the pressor activity elicited by noradrenaline (5 x 10(-8) - 5 x 10(-6) g/kg, i.v.) or tyramine (10(-5) - 5 x 10(-5) g/kg i.v.) was observed in any treatment group. In conclusion, chronic oral treatment with indapamide or propranolol, prevented the onset of DOCA-salt hypertension in rats. A long lasting antihypertensive action of indapamide involving the sympathetic nervous system is also indicated.
在雄性斯普拉格 - 道利大鼠中,通过在饮食中给予吲达帕胺(0.5或10.0毫克/千克)或普萘洛尔(60毫克/千克)进行为期11周的口服治疗,可预防去氧皮质酮 - 盐性高血压的发生。在第4、5、6、7和11周时,吲达帕胺治疗组的体重显著(P < 0.01)高于对照组,而在第11周时,普萘洛尔治疗组的体重和食物摄入量显著(P < 0.05)低于对照组。仅在吲达帕胺治疗的动物中测量到心脏湿重显著降低(P < 0.001)。在治疗的第11周,任何组均未检测到显著的利尿或利钠作用。当所有组在停药四周后接受增加的盐负荷时,只有吲达帕胺(10毫克/千克)治疗的动物血压未升高。在停药六周后进行的血管反应性研究表明,在吲达帕胺(10毫克/千克)治疗的去脑大鼠中,电刺激整个交感神经传出纤维引起的升压活性显著(P < 0.01)降低。在任何治疗组中,去甲肾上腺素(5×10⁻⁸ - 5×10⁻⁶克/千克,静脉注射)或酪胺(10⁻⁵ - 5×10⁻⁵克/千克,静脉注射)引起的升压活性均无显著差异。总之,吲达帕胺或普萘洛尔的慢性口服治疗可预防大鼠去氧皮质酮 - 盐性高血压的发生。还表明吲达帕胺具有涉及交感神经系统的持久降压作用。